Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Investor Presentation (March 2023)
18 slides from Nova Eye Medical's investor presentation, March 2023
Slide 1: Investor Presentation
Investor Presentation Nova Eye Medical Limited (ASX:EYE) March 2023 Addressing the two leading causes of blindness in the developed world
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any st
Slide 3: Financials and Corporate Snapshot
ASX: EYE Financials and Corporate Snapshot Australian Securities EYE 9% 1 Exchange Ticker Management + Board ASX Ownership (fully diluted) Nova Eye Medical Limited 146M 1 A$15.2M 2 A$24.9M 2 Shares on Issue Revenues Net Assets (based on 12 months) A$34M 1 A$3.6M 2 Market Capitalisation Cash (Includi
Slide 4: Executive Summary
Executive Summary • Nova Eye pioneered the fastest growing segment in the burgeoning ophthalmic market; canal surgery for glaucoma, and holds over 100 patents in this domain • Nova Eye is one of three principal participants in the canal surgery segment with a forecast segment CAGR of 19% over the fi
Slide 5: Business Snapshot
ASX: EYE Business Snapshot Focused on vision and flighting blindness, Nova Eye Medical leads the way in glaucoma and age-related macular degeneration, the leading causes of blindness in the developed world. Nova Eye Medical, Glaucoma AlphaRET, AMD Progress 2RT® to market-ready status with Develop, m
Slide 6: Glaucoma Market – accessing fast growing segment
Glaucoma Market – accessing fast growing segment Glaucoma interventions1 (2022 to 2027) Surgical glaucoma interventions are forecast to grow Glaucoma surgical 20.0% at 14.7% per annum globally over the next 5 years. device intervention1 14.70% Compound The fastest growing form of glaucoma surgery (2
Slide 7: Canal Surgery Segment Market Growth
Canal Surgery Segment Market Growth Global Canal Surgery Procedures 2017 to 2027 ('000's) 800 Forecast growth 20% 700 Number of procedures ('000's) 600 500 400 300 200 100 0 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 • Canal Surgery Segment Procedures growth rate of 20% forecast between
Slide 8: The superior features of iTrack Advance
8 The superior features of iTrackTM Advance position us for significant sales growth from the fast-growing canal surgery segment. • Launched in markets outside of USA and China in June 2022. • USA launch pending finalisation of FDA clearance
Slide 9: Introduced in 2008: Microcatheter designed for canaloplasty
• Introduced in 2008 • Microcatheter designed for canaloplasty • Strong body of clinical evidence but technically challenging– requires use of forceps, cutting instruments • Used predominantly by glaucoma surgeons nova-eye.com | 9
Slide 10: Clinically Significant Features iTrack Advance vs Other Canal Surgery Devices
Clinically Significant Features iTrackTM Advance vs Other Canal Surgery Devices Canal Surgery Ocular Pressure Medication Adverse Treatment of Method of Delivery Navigation Device Reduction @ 12 reduction Event Rate Canal Action Capacity months @ 12 months Light iTrackTM 68%¹ 360° beacon at (original
Slide 11: iTrack Advance expected to broaden customer base
The new iTrack™ Advance is expected to broaden Nova Eye Medicals 200 1,2001 customer base significantly in the USA. The device will not only appeal existing surgeon estimated glaucoma to glaucoma surgeons but also anterior segment surgeons / customers surgeon market comprehensive surgeons, expanding
Slide 12: H1FY23 Glaucoma Operating Result
H1FY23 Glaucoma Operating Result GLAUCOMA SEGMENT H1 FY23 Investments iTrack™Advance A $'000’s1 US $'000’s • Training of early adopter U.S. surgeons prior to U.S. launch • Increased tradeshow attendance and podium presence in Europe H1FY22 H1FY23 H1FY22 H1FY23 • Establishment of clinical training te
Slide 13: AlphaRET for AMD
AlphaRET for AMD • Age-related macular degeneration (AMD) is the leading cause of blindness 2RT® is a proprietary, world-first in industrialised countries in people over the age of 50 years. nanosecond laser therapy to • Late-stage Wet AMD market is currently the only market served (drug therapy tre
Slide 14: Overview of AMD Market
Overview of AMD Market Intermediate stage disease - AlphaRET Late stage macular degeneration (Treats underlying causes of AMD.) Intermediate Wet Dry Intermediate AMD (CNV) AMD (GA) AMD AMD Choroidal Neovascularization Geographic Atrophy 54 million 15 million 14 million 55 million people worldwide(1)
Slide 15: 2RT Development Milestones and Plan
2RT® Development Milestones and Plan Our strategy for 2RT® is to undertake a confirmatory pivotal clinical study at sites in Europe, Australia, Canada and ultimately the USA to gain FDA clearance for the treatment of intermediate AMD funded by partners. ✓ PRE-CLINCAL WORK Completed Investigational D
Slide 16: Update on iTrack Advance in USA
Update on iTrackTM Advance in USA • As previously announced, iTrackTM Advance is currently progressing through the US FDA 510(k) pathway. • FDA has recently requested that we file two final administrative changes to our documentation. This documentation has now been submitted. • We anticipate FDA cl
Slide 17: Nova Eye Group Outlook
Nova Eye Group Outlook Sales of new iTrack™ Advance in the USA are expected to drive significant sales growth during the current and future fiscal years. Operating expenditure will increase to support the expansion of USA commercial infrastructure with the underlying operating results for the glauco
Slide 18: Medic Limite
Limite Medic Nova Eye al d Tom Spurling Mark Flynn Kate Hunt Managing Director Investor Relations Chief Commercial Officer M: +61 417 818 658 M: +61 416 068 733 M: +61 404 080 679 E: tspurling@nova-eye.com E: mflynn@nova-eye.com E: khunt@nova-eye.com
Nova Eye Medical — Investor Presentation (March 2023) on 6ix